Abstract:Abstract The confirmation of target engagement for candidate drugs is a fundamental requisite in drug discovery. A significant portion of projects fail to reach the clinic due to lack of efficacy or failure to show lead candidates interacting with the intended target in a more complex environment. The utility of using the CETSA® (CEllular Thermal Shift Assay) technology to measure target engagement in intact cells is increasingly exploited in high throughput screening, where examples demonstrate low false positive rates in screens of up to 500K compounds. The p53 tumor suppressor protein, a crucial guardian against cancer, functions as a transcription factor that mediates cancer suppression by regulating genes involved in a wide range of cellular processes such as DNA repair, cell cycle and apoptosis. Unfortunately, frequent mutations in the TP53 gene hinder p53's tumor suppressor role in human cancers, thus designating it as a promising target for anticancer therapy. However, attempts to restore p53 function for therapeutic purposes have not yet advanced to clinical approval, highlighting the complexities in leveraging p53 for cancer treatment. Its undruggable nature, attributed to the absence of accessible deep pockets, lack of enzymatic activity, and its intracellular location, further complicates targeted interventions with both low and high molecular weight drugs. Here, we demonstrate the analysis of a high-throughput plate based CETSA® HT screen on the challenging target p53, performed using AlphaLISA® SureFire® UltraTM technology and our newly developed high-throughput screening platform. Hits identified from this screen are privileged from the onset by binding to the target in a physiologically relevant cellular matrix and in a binding-mode agnostic way. This is in contrast to traditional screening methods targeting activity or in vitro interaction where cellular activity is addressed in later stages. This assay cascade highlights a rapid target-to-hit lead generation strategy placing the emphasis on finding chemical matter that interacts with endogenous target in living cells first, followed by analysis of hit material activity. The ‘shortcut’ to chemical matter active in living cells represents significant potential cost savings in comparison to assay development time on recombinantly produced proteins and/or modified cell lines for traditional HTS screening approaches that still rely on target engagement assessment downstream. Citation Format: Merve Kacal, Tomas Friman, Laurence Arnold, Victoria Brehmer, Daniel Martinez Molina, Stina Lundgren. CETSA HT: Employing rapid high-throughput target engagement technology in primary screening of P53 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3097.

Compartmentalization of Enhanced Biomolecular Interactions for High-Throughput Drug Screening in Test Tubes

Phase-separated condensate-aided enrichment of biomolecular interactions for high-throughput drug screening in test tubes

A Sandwiched Microarray Platform for Benchtop Cell-Based High Throughput Screening

Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1

Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes

A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1

Screening of Small-Molecule Inhibitors of Protein-Protein Interaction with Capillary Electrophoresis Frontal Analysis.

High-Throughput Screening Based on Label-Free Detection of Smallmolecule Microarrays

Methods and Techniques of Capillary Electrophoresis for Drug Screening

High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery

Phase Separation-Based Biochemical Assays for Biomolecular Interactions.

High-throughput Screening Based on Small-Molecule Microarrays and OI-RD Microscope

Cell-based 3D Bionic Screening by Mimicking the Drug-Receptor Interaction Environment in Vivo.

Completing the Screen: Biochemical Cascades to Prioritize HTS Output

Application of Capillary Electrophoresis to Investigate Biomolecular Interactions and Drug Screening

High throughput proteome screening for novel drug targets

Capillary electrophoresis for screening of 20S proteasome inhibitors.

Rapid Screening of Multi-Target Antitumor Drugs by Nonimmobilized Tumor Cells/tissues Capillary Electrophoresis

Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to P53-Mdm2 Interaction Inhibitors

Use of Activity-Based Probes to Develop High Throughput Screening Assays That Can Be Performed in Complex Cell Extracts

Abstract 3097: CETSA HT: Employing rapid high-throughput target engagement technology in primary screening of P53